pamidronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 2048 40391-99-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pamidronic acid
  • pamidronate disodium
  • pamidronate
  • pamidronate disodium hydrate
An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies.
  • Molecular weight: 235.07
  • Formula: C3H11NO7P2
  • CLOGP: -4.32
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 6
  • TPSA: 161.31
  • ALOGS: -1.17
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
60 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 46 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.47 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 1 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.70 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 32 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT1,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 62
kinase-selectivity-class AURKA,AURKB,AXL,BMX,BRAF,CDK1,CDK2,CDK4,CDK6,CDK9,CHUK,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAPK7,PAK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 32
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 1991 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 820.44 18.50 278 12495 38825 90576849
Osteonecrosis 767.36 18.50 240 12533 26001 90589673
Bone disorder 259.82 18.50 104 12669 23016 90592658
Tooth extraction 225.92 18.50 78 12695 11435 90604239
Plasma cell myeloma 206.06 18.50 105 12668 40723 90574951
Atypical femur fracture 188.50 18.50 59 12714 6362 90609312
Sequestrectomy 172.24 18.50 36 12737 753 90614921
Bone debridement 154.52 18.50 27 12746 204 90615470
Malignant neoplasm progression 142.45 18.50 119 12654 106751 90508923
Infusion site coldness 121.02 18.50 22 12751 213 90615461
Debridement 119.24 18.50 29 12744 1220 90614454
Metastases to bone 118.29 18.50 62 12711 25443 90590231
Gamma-glutamyltransferase decreased 111.60 18.50 22 12751 339 90615335
Hypocalcaemia 110.91 18.50 71 12702 42297 90573377
Pain in jaw 109.99 18.50 74 12699 47911 90567763
Exposed bone in jaw 107.70 18.50 32 12741 2894 90612780
Femur fracture 105.47 18.50 71 12702 46011 90569663
Bone sequestrum 105.04 18.50 27 12746 1426 90614248
Actinomycosis 101.45 18.50 25 12748 1111 90614563
Osteomyelitis 96.88 18.50 56 12717 27790 90587884
Bone pain 86.65 18.50 71 12702 61912 90553762
Infusion site induration 79.58 18.50 22 12751 1537 90614137
Hypercalcaemia 78.92 18.50 53 12720 34187 90581487
Cardiac output decreased 78.87 18.50 20 12753 1000 90614674
Post-traumatic neck syndrome 69.20 18.50 22 12751 2492 90613182
Toothache 67.62 18.50 41 12732 22189 90593485
Vasodilatation 66.23 18.50 22 12751 2862 90612812
Vein disorder 62.48 18.50 25 12748 5511 90610163
Jaw disorder 55.53 18.50 23 12750 5536 90610138
Bone lesion excision 55.20 18.50 9 12764 42 90615632
Toxic neuropathy 53.72 18.50 13 12760 535 90615139
Infusion site haemorrhage 52.75 18.50 22 12751 5389 90610285
Jaw operation 52.44 18.50 14 12759 857 90614817
Mean cell haemoglobin decreased 51.66 18.50 22 12751 5673 90610001
Retinal detachment 51 18.50 23 12750 6799 90608875
Spinal pain 47.75 18.50 29 12744 15738 90599936
Urine odour abnormal 46.59 18.50 22 12751 7222 90608452
Osteitis 45.94 18.50 18 12755 3755 90611919
Stress fracture 45.90 18.50 23 12750 8588 90607086
Abscess jaw 45.10 18.50 14 12759 1467 90614207
Wound treatment 42.71 18.50 9 12764 196 90615478
Tibia fracture 40.73 18.50 19 12754 6068 90609606
Pathological fracture 40.59 18.50 22 12751 9638 90606036
Blood parathyroid hormone increased 40.45 18.50 16 12757 3421 90612253
Osteosclerosis 40.22 18.50 17 12756 4303 90611371
Osteotomy 39.41 18.50 9 12764 287 90615387
Incontinence 38.86 18.50 24 12749 13411 90602263
Fistula 38.58 18.50 23 12750 12066 90603608
Peripheral coldness 38.13 18.50 24 12749 13868 90601806
Disease progression 37.70 18.50 74 12699 156541 90459133
Breast cancer 37.55 18.50 42 12731 53719 90561955
Bone lesion 36.70 18.50 18 12755 6419 90609255
Osteolysis 36.52 18.50 15 12758 3535 90612139
Blood creatinine decreased 36.49 18.50 18 12755 6497 90609177
Impaired healing 36.48 18.50 93 12680 234106 90381568
Neoplasm progression 34.99 18.50 37 12736 44449 90571225
Wound closure 33.28 18.50 7 12766 151 90615523
Water intoxication 33.23 18.50 9 12764 582 90615092
Mineral metabolism disorder 33.11 18.50 6 12767 57 90615617
Poor venous access 32.93 18.50 25 12748 19502 90596172
Arthropathy 32.79 18.50 6 12767 366236 90249438
Skin sensitisation 32.62 18.50 10 12763 1005 90614669
Tumour marker increased 32.40 18.50 16 12757 5791 90609883
Tooth abscess 32.16 18.50 23 12750 16390 90599284
Blood potassium increased 31.59 18.50 25 12748 20724 90594950
Contraindicated product administered 31.49 18.50 4 12769 320135 90295539
Bone formation decreased 30.52 18.50 6 12767 91 90615583
Mucosal inflammation 30.35 18.50 39 12734 57586 90558088
Computerised tomogram abnormal 30.15 18.50 12 12761 2607 90613067
Hepatic enzyme increased 30.04 18.50 7 12766 360729 90254945
Gastritis 29.81 18.50 33 12740 41720 90573954
Joint swelling 29.76 18.50 17 12756 503283 90112391
Blood test abnormal 29.26 18.50 24 12749 20928 90594746
Hyperbaric oxygen therapy 28.70 18.50 5 12768 37 90615637
Body temperature decreased 28.57 18.50 25 12748 23791 90591883
Pneumonia influenzal 28.38 18.50 11 12762 2229 90613445
Tooth disorder 28.34 18.50 28 12745 31062 90584612
Metastases to liver 28.24 18.50 27 12746 28780 90586894
Death 28.10 18.50 133 12640 456418 90159256
Osteoradionecrosis 27.68 18.50 6 12767 150 90615524
Tumour lysis syndrome 27.47 18.50 18 12755 11134 90604540
Tumour marker abnormal 27.09 18.50 7 12766 377 90615297
Wound dehiscence 26.54 18.50 14 12759 5808 90609866
Musculoskeletal stiffness 26.23 18.50 5 12768 296527 90319147
Therapeutic product effect decreased 26.05 18.50 4 12769 277567 90338107
Bone fistula 26.01 18.50 5 12768 67 90615607
Discomfort 25.64 18.50 4 12769 274331 90341343
Feeling cold 25.52 18.50 25 12748 27440 90588234
Neuropathy peripheral 25.17 18.50 58 12715 136912 90478762
Aspergilloma 24.00 18.50 6 12767 283 90615391
Neutrophil count decreased 23.88 18.50 39 12734 71493 90544181
Wheezing 23.35 18.50 3 12770 238077 90377597
Rheumatoid arthritis 23.27 18.50 11 12762 362603 90253071
Callus formation delayed 23.16 18.50 4 12769 28 90615646
Gingival swelling 22.70 18.50 12 12761 5001 90610673
Post procedural diarrhoea 22.42 18.50 6 12767 371 90615303
Condition aggravated 22.17 18.50 31 12742 595514 90020160
Blood calcium increased 21.58 18.50 16 12757 12042 90603632
Femoral neck fracture 21.58 18.50 15 12758 10218 90605456
Wound 21.35 18.50 8 12765 302972 90312702
Infusion site thrombosis 21.28 18.50 5 12768 181 90615493
Fracture nonunion 21.27 18.50 9 12764 2283 90613391
Oedema peripheral 21.14 18.50 82 12691 257833 90357841
Anaemia macrocytic 20.86 18.50 11 12762 4561 90611113
Oral surgery 20.80 18.50 8 12765 1588 90614086
Lymphatic disorder 20.80 18.50 6 12767 489 90615185
Periodontal destruction 20.66 18.50 3 12770 5 90615669
Purulence 20.64 18.50 8 12765 1621 90614053
Mobility decreased 20.60 18.50 5 12768 250729 90364945
Osteomyelitis chronic 20.52 18.50 6 12767 513 90615161
Spinal compression fracture 20.39 18.50 17 12756 15161 90600513
Focal segmental glomerulosclerosis 19.65 18.50 8 12765 1843 90613831
Adenocarcinoma of colon 19.52 18.50 9 12764 2797 90612877
Flushing 19.12 18.50 40 12733 88451 90527223
Nephrocalcinosis 19.05 18.50 7 12766 1225 90614449
Foetal heart rate deceleration abnormality 18.93 18.50 6 12767 673 90615001

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 439.93 20.30 145 6948 15720 42598522
Osteonecrosis of jaw 312.90 20.30 118 6975 18931 42595311
Plasma cell myeloma 172.40 20.30 104 6989 47474 42566768
Tooth extraction 163.41 20.30 53 7040 5427 42608815
Bone disorder 161.44 20.30 55 7038 6558 42607684
Bone debridement 111.04 20.30 20 7073 152 42614090
Exposed bone in jaw 84.50 20.30 24 7069 1565 42612677
Sequestrectomy 81.12 20.30 16 7077 207 42614035
Pain in jaw 80.50 20.30 42 7051 14460 42599782
Atypical femur fracture 79.19 20.30 17 7076 341 42613901
Debridement 76.50 20.30 20 7073 954 42613288
Hypercalcaemia 71.88 20.30 42 7051 18016 42596226
Osteomyelitis 66.31 20.30 40 7053 18183 42596059
Actinomycosis 60.70 20.30 15 7078 569 42613673
Hyperbaric oxygen therapy 58.19 20.30 9 7084 22 42614220
Nephrocalcinosis 55.96 20.30 15 7078 788 42613454
Tibia fracture 51.72 20.30 17 7076 1811 42612431
Neuropathy peripheral 50.77 20.30 73 7020 101780 42512462
Femur fracture 50.43 20.30 27 7066 9785 42604457
Hypocalcaemia 46.05 20.30 39 7054 30134 42584108
Purulent discharge 45.77 20.30 18 7075 3211 42611031
Acute generalised exanthematous pustulosis 45.15 20.30 24 7069 8571 42605671
Impaired healing 38.98 20.30 28 7065 17025 42597217
Hepatitis B 38.85 20.30 20 7073 6691 42607551
Jaw fracture 38.56 20.30 12 7081 1072 42613170
Bone sequestrum 37.46 20.30 10 7083 517 42613725
Bone lesion excision 36.16 20.30 5 7088 3 42614239
Stress fracture 31.00 20.30 10 7083 1004 42613238
Jaw operation 30.17 20.30 7 7086 202 42614040
Foot fracture 28.93 20.30 16 7077 6175 42608067
Pustular psoriasis 27.15 20.30 11 7082 2118 42612124
Pneumonia 26.44 20.30 139 6954 422010 42192232
Fistula 25.29 20.30 16 7077 7896 42606346
Pancytopenia 24.64 20.30 58 7035 117685 42496557
Wound closure 24.53 20.30 5 7088 77 42614165
Jaw disorder 23.75 20.30 10 7083 2123 42612119
Carcinoid tumour 23.44 20.30 6 7087 263 42613979
Deep vein thrombosis 23.18 20.30 44 7049 76913 42537329
CSF white blood cell count decreased 22.49 20.30 4 7089 28 42614214
Plasmacytoma 22.39 20.30 12 7081 4352 42609890
Bone lesion 22.01 20.30 11 7082 3455 42610787
Chronic fatigue syndrome 21.94 20.30 6 7087 340 42613902
Plasma cell leukaemia 21.47 20.30 8 7085 1232 42613010
Bone pain 21.45 20.30 23 7070 23769 42590473
Bone swelling 21.34 20.30 6 7087 377 42613865
Drug interaction 21.15 20.30 9 7084 266990 42347252
Maxillofacial operation 21.03 20.30 3 7090 3 42614239

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 1050.80 17.21 358 16255 47659 110525027
Osteonecrosis 1043.78 17.21 327 16286 33414 110539272
Bone disorder 404.87 17.21 143 16470 21049 110551637
Tooth extraction 401.54 17.21 126 16487 12865 110559821
Plasma cell myeloma 328.52 17.21 169 16444 62767 110509919
Bone debridement 263.73 17.21 47 16566 375 110572311
Sequestrectomy 237.60 17.21 48 16565 788 110571898
Debridement 193.66 17.21 47 16566 1836 110570850
Atypical femur fracture 190.78 17.21 60 16553 6159 110566527
Pain in jaw 172.26 17.21 103 16510 51074 110521612
Actinomycosis 171.92 17.21 40 16573 1300 110571386
Osteomyelitis 167.30 17.21 90 16523 36510 110536176
Bone sequestrum 148.68 17.21 35 16578 1198 110571488
Exposed bone in jaw 143.34 17.21 43 16570 3768 110568918
Metastases to bone 129.15 17.21 72 16541 31300 110541386
Hypocalcaemia 128.37 17.21 94 16519 65272 110507414
Hypercalcaemia 126.86 17.21 82 16531 46575 110526111
Malignant neoplasm progression 126.19 17.21 143 16470 174424 110398262
Femur fracture 125.47 17.21 80 16533 44389 110528297
Infusion site coldness 115.85 17.21 22 16591 257 110572429
Gamma-glutamyltransferase decreased 107.89 17.21 22 16591 379 110572307
Bone pain 100.14 17.21 81 16532 65052 110507634
Bone lesion excision 89.85 17.21 14 16599 42 110572644
Hyperbaric oxygen therapy 88.21 17.21 14 16599 49 110572637
Jaw operation 81.36 17.21 20 16593 824 110571862
Infusion site induration 80.91 17.21 22 16591 1354 110571332
Stress fracture 74.04 17.21 31 16582 7190 110565496
Fistula 73.76 17.21 39 16574 15260 110557426
Jaw disorder 72.96 17.21 28 16585 5184 110567502
Post-traumatic neck syndrome 67.13 17.21 22 16591 2573 110570113
Nephrocalcinosis 66.20 17.21 20 16593 1794 110570892
Cardiac output decreased 63.61 17.21 20 16593 2049 110570637
Impaired healing 63.01 17.21 109 16504 196608 110376078
Wound treatment 60.16 17.21 12 16601 184 110572502
Osteotomy 59.57 17.21 13 16600 314 110572372
Vasodilatation 59.24 17.21 22 16591 3722 110568964
Wound closure 58.72 17.21 12 16601 209 110572477
Toothache 58.14 17.21 39 16574 23536 110549150
Vein disorder 57.93 17.21 25 16588 6245 110566441
Infusion site haemorrhage 54.85 17.21 22 16591 4576 110568110
Bone lesion 51.85 17.21 24 16589 7063 110565623
Osteolysis 50.95 17.21 22 16591 5501 110567185
Pathological fracture 50.56 17.21 28 16585 12004 110560682
Purulent discharge 48.77 17.21 23 16590 7060 110565626
Tibia fracture 47.24 17.21 22 16591 6563 110566123
Blood parathyroid hormone increased 46.13 17.21 19 16594 4229 110568457
Mean cell haemoglobin decreased 45.45 17.21 22 16591 7152 110565534
Urine odour abnormal 44.76 17.21 22 16591 7393 110565293
Neuropathy peripheral 44.43 17.21 89 16524 179188 110393498
Jaw fracture 44.34 17.21 17 16596 3139 110569547
Toxic neuropathy 43.65 17.21 13 16600 1110 110571576
Osteitis 42.56 17.21 18 16595 4278 110568408
Abscess jaw 41.43 17.21 14 16599 1800 110570886
Foot fracture 39.73 17.21 32 16581 25514 110547172
Spinal pain 39.46 17.21 28 16585 18487 110554199
Drug interaction 39.45 17.21 13 16600 500170 110072516
Retinal detachment 39.04 17.21 23 16590 11077 110561609
Osteosclerosis 38.45 17.21 17 16596 4498 110568188
Peripheral coldness 37.13 17.21 27 16586 18513 110554173
Hepatitis B 36.68 17.21 21 16592 9591 110563095
Maxillofacial operation 35.08 17.21 5 16608 6 110572680
Pneumonia influenzal 34.59 17.21 15 16598 3790 110568896
Tooth disorder 33.75 17.21 31 16582 29478 110543208
Adenocarcinoma of colon 33.40 17.21 17 16596 6151 110566535
Body temperature decreased 33.21 17.21 34 16579 36901 110535785
Incontinence 32.81 17.21 24 16589 16611 110556075
Hepatic enzyme increased 31.93 17.21 5 16608 320887 110251799
Skin sensitisation 31.03 17.21 10 16603 1109 110571577
Tumour marker increased 30.50 17.21 15 16598 5045 110567641
Bone fistula 30.39 17.21 6 16607 87 110572599
Tooth abscess 30.21 17.21 24 16589 18765 110553921
Osteomyelitis chronic 30 17.21 9 16604 788 110571898
Plasmacytoma 29.94 17.21 15 16598 5247 110567439
Metastases to lung 29.88 17.21 26 16587 23037 110549649
Blood creatinine decreased 29.71 17.21 18 16595 9119 110563567
Toxicity to various agents 29.28 17.21 18 16595 480537 110092149
Neoplasm progression 29.27 17.21 42 16571 64553 110508133
Acute generalised exanthematous pustulosis 29.24 17.21 25 16588 21639 110551047
Water intoxication 28.36 17.21 9 16604 950 110571736
Tumour marker abnormal 28.34 17.21 7 16606 294 110572392
Oral surgery 28.31 17.21 10 16603 1466 110571220
Dental operation 28.29 17.21 10 16603 1469 110571217
Computerised tomogram abnormal 27.77 17.21 13 16600 3923 110568763
Wheezing 27.74 17.21 3 16610 255227 110317459
Metastases to skin 27.42 17.21 11 16602 2288 110570398
Gingival swelling 26.87 17.21 14 16599 5316 110567370
Contraindicated product administered 26.77 17.21 3 16610 248264 110324422
Foetal heart rate deceleration abnormality 26.64 17.21 6 16607 168 110572518
Poor venous access 26.57 17.21 25 16588 24497 110548189
Metastases to liver 25.54 17.21 29 16584 35357 110537329
Arthropathy 25.39 17.21 6 16607 287516 110285170
Blood potassium increased 25.28 17.21 28 16585 33221 110539465
Tumour lysis syndrome 25.27 17.21 27 16586 30774 110541912
Deep vein thrombosis 25.07 17.21 61 16552 139826 110432860
Joint swelling 25.07 17.21 18 16595 442827 110129859
Periodontal destruction 24.78 17.21 4 16609 16 110572670
Gastritis 24.45 17.21 35 16578 53664 110519022
Wound dehiscence 24.14 17.21 15 16598 7947 110564739
Purulence 23.89 17.21 10 16603 2317 110570369
Plastic surgery 23.86 17.21 5 16608 99 110572587
Oedema peripheral 23.70 17.21 105 16508 328555 110244131
Arteriovenous fistula thrombosis 23.52 17.21 7 16606 596 110572090
Stem cell transplant 23.38 17.21 12 16601 4415 110568271
Condition aggravated 23.38 17.21 47 16566 734789 109837897
Callus formation delayed 23.29 17.21 4 16609 25 110572661
Gingivitis 22.89 17.21 16 16597 10315 110562371
Pericarditis 22.76 17.21 3 16610 219111 110353575
Bone swelling 22.72 17.21 9 16604 1812 110570874
Product dose omission issue 22.63 17.21 10 16603 321772 110250914
Oral cavity fistula 22.62 17.21 7 16606 680 110572006
Asthma 22.54 17.21 5 16608 250286 110322400
Spinal compression fracture 22.36 17.21 20 16593 18372 110554314
Osteoradionecrosis 22.20 17.21 5 16608 140 110572546
Therapeutic product effect decreased 21.77 17.21 5 16608 244311 110328375
Blood test abnormal 21.63 17.21 24 16589 28530 110544156
Disease progression 21.55 17.21 83 16530 243951 110328735
Lymphatic disorder 21.24 17.21 6 16607 425 110572261
Oedema mucosal 20.78 17.21 9 16604 2267 110570419
Blood calcium increased 20.72 17.21 19 16594 18021 110554665
Hypophagia 20.66 17.21 32 16581 52594 110520092
Fracture nonunion 20.61 17.21 8 16605 1526 110571160
Post procedural diarrhoea 20.48 17.21 6 16607 484 110572202
Intentional product use issue 20.32 17.21 6 16607 247900 110324786
Anaemia macrocytic 20.24 17.21 13 16600 7290 110565396
Gingival erythema 19.93 17.21 7 16606 1009 110571677
Actinomycotic skin infection 18.79 17.21 3 16610 11 110572675
Blood creatinine increased 18.49 17.21 65 16548 182824 110389862
Focal segmental glomerulosclerosis 18.39 17.21 10 16603 4135 110568551
Placental insufficiency 18.28 17.21 7 16606 1287 110571399
Feeling cold 18.26 17.21 24 16589 33963 110538723
Alopecia 17.94 17.21 17 16596 364736 110207950
Loose tooth 17.71 17.21 9 16604 3244 110569442
Musculoskeletal stiffness 17.71 17.21 10 16603 279812 110292874
Aspergilloma 17.59 17.21 6 16607 793 110571893
Breast cancer 17.37 17.21 25 16588 38517 110534169
Bladder transitional cell carcinoma stage 0 17.28 17.21 4 16609 127 110572559

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M05BA03 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
FDA CS M0006519 Diphosphonates
FDA EPC N0000175579 Bisphosphonate
MeSH PA D050071 Bone Density Conservation Agents
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50646 bone density conservation agent

Related Drugs by ATC class:

M05BA Bisphosphonates 7 drugs
alendronic acidclodronic acidetidronic acidibandronic acidrisedronic acidtiludronic acidzoledronic acid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Osteolytic Lesions of Multiple Myeloma indication
Osteolytic Bone Metastases of Breast Cancer indication
Drug-induced osteoporosis off-label use 14651005
Prevention of Glucocorticoid-Induced Osteoporosis off-label use
Bone Metastases off-label use
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Periodontitis contraindication 41565005 DOID:824
Hypokalemia contraindication 43339004
Kidney disease contraindication 90708001 DOID:557
Hypomagnesemia contraindication 190855004
Pregnancy, function contraindication 289908002
Aseptic necrosis of bone of jaw contraindication 441809006
Thyroid Surgery contraindication
Invasive Dental Procedure contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.71 acidic
pKa2 4.78 acidic
pKa3 5.76 acidic
pKa4 9.83 acidic
pKa5 13.04 acidic
pKa6 11.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 7.25 CHEMBL CHEMBL
Farnesyl pyrophosphate synthase Enzyme Ki 6.72 CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Enzyme Ki 4.30 CHEMBL

External reference:

IDSource
D00941 KEGG_DRUG
109552-15-0 SECONDARY_CAS_RN
4020311 VANDF
4020543 VANDF
C3714572 UMLSCUI
CHEBI:7903 CHEBI
210 PDB_CHEM_ID
CHEMBL834 ChEMBL_ID
DB00282 DRUGBANK_ID
CHEMBL3989401 ChEMBL_ID
4674 PUBCHEM_CID
7259 IUPHAR_LIGAND_ID
6305 INN_ID
OYY3447OMC UNII
105443 RXNORM
42496 MMSL
5226 MMSL
d00601 MMSL
003616 NDDF
005066 NDDF
396032007 SNOMEDCT_US
420442001 SNOMEDCT_US
772820008 SNOMEDCT_US
96288007 SNOMEDCT_US
D000077268 MESH_DESCRIPTOR_UI
OYY3447OMC INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-324 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-325 INJECTION, SOLUTION 6 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-326 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-430 INJECTION 3 mg INTRAVENOUS ANDA 35 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-430 INJECTION 3 mg INTRAVENOUS ANDA 35 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-446 INJECTION 9 mg INTRAVENOUS ANDA 35 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-446 INJECTION 9 mg INTRAVENOUS ANDA 35 sections